Epigenetic Alterations in AML
N/A
17 Years
Both
Leukemia
Trial Information
Epigenetic Alterations in AML
OBJECTIVES:
- Map key histone modifications and cytosine methylation in leukemia cell lines with
defined oncogenic mutations.
- Acquire genome-wide maps of key histone modifications and cytosine methylation for
primary leukemia in samples from patients with acute myeloid leukemia (AML).
- Investigate functional relationships between genetic and epigenetic landscapes in AML.
OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone
modification and cytosine methylation. Genome-wide locations of 5 histone modifications are
analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by
high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data
(sequence analysis, expression array, SNP array).
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia
- Primary leukemia samples from the Children Oncology Group (COG) bank with sufficient
number of cells (500,000-1 million cells) with > 80% of leukemia blasts
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Relationships between genetic and epigenetic landscapes in AML
Safety Issue:
No
Principal Investigator
Soheil Meshinchi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Federal Government
Study ID:
CDR0000671474
NCT ID:
NCT01139931
Start Date:
October 2009
Completion Date:
Related Keywords:
- Leukemia
- childhood acute myeloid leukemia/other myeloid malignancies
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
